Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 36.60%
Price change 2019 → 2020: 12.49%
Price change 2020 → 2021: 23.82%
Price change 2021 → 2022: -29.45%
Price change 2022 → 2023: -4.93%
Price change 2023 → 2024: 1.84%
Price change 2024 → 2025: -30.50%
Price change 2025 → 2026: -11.58%
Price change 2026 (year to date): -9.94%
Financial growth
Revenue CAGR (8 years): 7.83%
Earnings CAGR (8 years): -0.80%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 1.40
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 22.89
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 0.33% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="COLO-B.CO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Coloplast A/S | 24.1 | 1.40 | +7.2 % | 🔒 |
| Charles River Laboratories International, Inc. | 34.1 | 0.97 | +8.8 % | – |
| Ipsen S.A. | 26.9 | 0.20 | +7.9 % | – |
| Sonova Holding AG | 31.4 | 0.66 | +5.6 % | – |
| BioNTech SE | – | 0.01 | +60.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Coloplast A/S over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2021 | 2.9 bn | 711 m | 24.8 % | n/a |
| 2022 | 3.3 bn | 694 m | 20.8 % | +16.2 % |
| 2023 | 3.6 bn | 705 m | 19.5 % | +8.5 % |
| 2024 | 4.0 bn | 745 m | 18.7 % | +10.3 % |
| 2025 | 4.1 bn | 536 m | 13.0 % | +3.1 % |
| 2026 | 4.3 bn | 453 m | 10.6 % | +3.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Coloplast A/S over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 633 m | 911 m | 788 m | 947 m | 511 m |
| Total Debt | 18.7 bn | 19.6 bn | 22.6 bn | 22.6 bn | 21.5 bn |
| Net Debt | 18.3 bn | 18.7 bn | 21.8 bn | 21.7 bn | 21.0 bn |
| Equity | 8.3 bn | 17.3 bn | 17.9 bn | 16.1 bn | 14.3 bn |
| Total assets | 35.0 bn | 48.2 bn | 48.1 bn | 48.4 bn | 46.3 bn |
| Operating cash flow | 5.1 bn | 4.2 bn | 2.8 bn | 6.6 bn | 8.0 bn |
| Investments (capex) | 1.1 bn | 1.2 bn | 1.2 bn | 1.4 bn | 1.6 bn |
| Free cash-flow | 4.0 bn | 3.0 bn | 1.6 bn | 5.3 bn | 6.6 bn |
| Share buybacks | 619 m | 0 | 0 | 0 | 0 |
| Dividends paid | 4.0 bn | 4.2 bn | 4.7 bn | 5.0 bn | 5.2 bn |
Amounts in DKK, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Coloplast A/S compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Coloplast A/S publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 28.9 bn | 5.6 bn | 25.45 (24.25 / 26.69) | 20.0 | 18 |
| 2027 | 31.0 bn | 5.8 bn | 26.26 (24.49 / 28.88) | 19.3 | 18 |
| 2028 | 33.0 bn | 6.3 bn | 28.39 (24.13 / 30.00) | 17.9 | 16 |
Amounts in DKK, the reporting currency.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Coloplast A/S
What is the Coloplast A/S share price?
Latest recorded price: 508.00 DKK on 13/11/2026, for a market cap of 16.9 bn USD.
What is the revenue of Coloplast A/S?
4.3 bn USD for fiscal year 2026, with net income of 453 m USD (net margin 10.6 %).
When does Coloplast A/S report its next earnings?
The next release is expected on 09/02/2027. EPS expected by analysts: 6.19.
What do analysts say about Coloplast A/S?
Out of 21 analysts: 3 buy or strong buy, 15 hold, 3 sell or strong sell.
What is the P/E ratio of Coloplast A/S?
Trailing 12-month P/E of 24.1.
Is Coloplast A/S stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DK0060448595) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Coloplast A/S have?
16,741 full-time employees according to the latest published profile.
Who runs Coloplast A/S?
Anders Lonning-Skovgaard is the company's chief executive.